Wednesday, 12 March 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 12 March 2025
News

Lilly pumps up Aussie radio deal

Posted 13 February 2025 AM 

Eli Lilly has seen potential in AdvanCell and expanded the scope and breadth of an existing strategic collaboration originally inked by Point Biopharma to advance novel radiopharmaceuticals for various cancers.

The Aussie clinical-stage radiopharmaceutical company’s therapeutic pipeline is powered by alpha 212, which is the isotope of Lead-212 (Pb-212) – and is led by a would-be challenger to Novartis prostate cancer drug Pluvicto. AdvanCell’s portfolio also comprises targeted alpha therapies for melanoma, pancreatic, and breast cancer.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (36)

Clinical & Medical, R&D (16)

Regulatory, Pharmacovigilance & QA (1)

Other (20)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.